BridgeMD
The RIME-IVF study - Investigation of RIsk factors in out-of-hospital-cardiac-arrest patients, and MEdical treatment in Idiopathic Ventricular Fibrillation patients
EU CTIS ID: 2024-518057-41-00
What this study is testing
To investigate the effect on beta-blocker treatment in IVF patients by ICD data (appropriate ATP and shock)
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Unexplained cardiac arrest survivors aged 18 or older
- All patients surviving a cardiac arrest will receive a minimum diagnostic work-up consisting of an ECG, a Holter monitor during admission, an echocardiography, consecutive blood samples during the first 24 hours, and a coronary angiography or a cardiac CT-scan. Further evaluation with SAECG, stress-ECG, Cardiac MRI, and Sodium-channel blocker testing will be performed subsequently
- All patients will have an ICD implanted
You likely can't join if
- Age under 18 years
- Explained cardiac arrest
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.